Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Operating Leases (2019 - 2025)

Historic Operating Leases for ImmunityBio (IBRX) over the last 7 years, with Q3 2025 value amounting to $41.4 million.

  • ImmunityBio's Operating Leases fell 536.15% to $41.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.4 million, marking a year-over-year decrease of 536.15%. This contributed to the annual value of $34.8 million for FY2024, which is 2304.31% down from last year.
  • Per ImmunityBio's latest filing, its Operating Leases stood at $41.4 million for Q3 2025, which was down 536.15% from $43.2 million recorded in Q2 2025.
  • ImmunityBio's 5-year Operating Leases high stood at $52.1 million for Q2 2022, and its period low was $16.6 million during Q1 2021.
  • Over the past 5 years, ImmunityBio's median Operating Leases value was $43.2 million (recorded in 2025), while the average stood at $41.9 million.
  • Its Operating Leases has fluctuated over the past 5 years, first surged by 23523.56% in 2021, then tumbled by 2304.31% in 2024.
  • ImmunityBio's Operating Leases (Quarter) stood at $40.1 million in 2021, then increased by 26.6% to $50.7 million in 2022, then fell by 10.82% to $45.2 million in 2023, then fell by 23.04% to $34.8 million in 2024, then grew by 19.02% to $41.4 million in 2025.
  • Its last three reported values are $41.4 million in Q3 2025, $43.2 million for Q2 2025, and $40.6 million during Q1 2025.